Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 5/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | PPARG | P37231 | 5/20 | 0.34 |
| ▸ | PPARD | Q03181 | 5/20 | 0.34 |
| ▸ | PPARA | Q07869 | 5/20 | 0.34 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.34 |
| ▸ | TLR2 | O60603 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | FABP4 | P15090 | 2/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15009749 | 0.98 | TSHR (0.44) | LMNATSHRNFKB1PMP22SLC22A6 | |
| SCHEMBL1247297 | 0.96 | TSHR (0.45) | LMNATSHRNFKB1PMP22SLC22A6 | |
| SCHEMBL5968591 | 0.90 | EGLN1 (0.39) | LMNATSHRSLC22A6FOLH1ALDH1A1 | |
| SCHEMBL2335885 | 0.83 | LMNA (0.61) | LMNATSHRNFKB1PMP22SLC22A6 | |
| SCHEMBL14432755 | 0.83 | DGKA (0.46) | LMNATSHRSLC22A6GPR84AKR1B1 | |
| SCHEMBL6738571 | 0.82 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL17204502 | 0.81 | DGKA (0.48) | LMNATSHRSLC22A6GPR84ALDH1A1 | |
| SCHEMBL7887094 | 0.81 | DGKA (0.48) | LMNATSHRSLC22A6GPR84ALDH1A1 | |
| SCHEMBL7262371 | 0.81 | DGKA (0.48) | LMNATSHRSLC22A6GPR84ALDH1A1 | |
| SCHEMBL5799523 | 0.81 | TSHR (0.63) | LMNATSHRNFKB1PMP22SLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11383006-B2 | Bioerodible cross-linked hydrogel implants and related methods of use | DOSE MEDICAL CORPORATION (US) | 2022-07-12 | — | — | US | claimed |
| EP-4009857-A1 | BIOERODIBLE CROSS-LINKED HYDROGEL IMPLANTS AND RELATED METHODS OF USE | DOSE Medical Corporation (US) | 2022-06-15 | — | — | EP | claimed |
| US-20210038769-A1 | BIOERODIBLE CROSS-LINKED HYDROGEL IMPLANTS AND RELATED METHODS OF USE | DOSE MEDICAL CORPORATION | 2021-02-11 | — | — | US | claimed |
| WO-2021026214-A1 | BIOERODIBLE CROSS-LINKED HYDROGEL IMPLANTS AND RELATED METHODS OF USE | DOSE MEDICAL CORPORATION (US) | 2021-02-11 | — | — | WO | claimed |
| US-20200375891-A1 | BIOERODIBLE CROSS-LINKED HYDROGEL IMPLANTS AND RELATED METHODS OF USE | DOSE MEDICAL CORP (US) | 2020-12-03 | — | — | US | claimed |
| WO-2020243602-A1 | BIOERODIBLE CROSS-LINKED HYDROGEL IMPLANTS AND RELATED METHODS OF USE | DOSE MEDICAL CORPORATION (US) | 2020-12-03 | — | — | WO | claimed |
| US-10550187-B2 | Extra luminal scaffold | INCEPT, LLC (US) | 2020-02-04 | — | — | US | claimed |
| EP-4344745-A2 | SUSTAINED RELEASE BIODEGRADABLE INTRACANALICULAR INSERTS COMPRISING A HYDROGEL AND CYCLOSPORINE | Ocular Therapeutix, Inc. (US) | 2024-04-03 | — | — | EP | disclosed |
| US-11938223-B2 | Shape changing drug delivery devices and methods | INCEPT, LLC (US) | 2024-03-26 | — | — | US | disclosed |
| EP-3973952-B1 | SUSTAINED RELEASE BIODEGRADABLE INTRACANALICULAR INSERTS COMPRISING A HYDROGEL AND CYCLOSPORINE | OCULAR THERAPEUTIX INC (US) | 2024-02-14 | — | — | EP | disclosed |
| US-20240041758-A1 | SUSTAINED RELEASE BIODEGRADABLE INTRACANALICULAR INSERTS COMPRISING A HYDROGEL AND CYCLOSPORINE | OCULAR THERAPEUTIX, INC. | 2024-02-08 | — | — | US | disclosed |
| US-11890343-B2 | Medical organogel processes and compositions | INCEPT, LLC (US) | 2024-02-06 | — | — | US | disclosed |
| EP-4279064-A2 | DRUG DELIVERY FROM HYDROGELS | Incept, LLC (US) | 2023-11-22 | — | — | EP | disclosed |
| US-20170143636-A1 | SHAPE CHANGING DRUG DELIVERY DEVICES AND METHODS | OCULAR THERAPEUTIX, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20160331738-A1 | DRUG DELIVERY FROM HYDROGELS | OCULAR THERAPEUTIX, INC. | 2016-11-17 | — | — | US | disclosed |
| US-20160166504-A1 | HYDROGEL DRUG DELIVERY IMPLANTS | OCULAR THERAPEUTIX, INC. | 2016-06-16 | — | — | US | disclosed |
| US-20160045602-A1 | MEDICAL ORGANOGEL PROCESSES AND COMPOSITIONS | OCULAR THERAPEUTIX, INC. | 2016-02-18 | — | — | US | disclosed |
| US-9205150-B2 | Medical organogel processes and compositions | INCEPT, LLC (US) | 2015-12-08 | — | — | US | disclosed |
| US-20130156752-A1 | MEDICAL ORGANOGEL PROCESSES AND COMPOSITIONS | INCEPT, LLC (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2008133534-A2 | CARBOHYDRATE-LIPID CONSTRUCTS AND THEIR USE IN PREVENTING OR TREATING VIRAL INFECTION | KODE BIOTECH LIMITED (NZ) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240041758-A1 | SUSTAINED RELEASE BIODEGRADABLE INTRACANALICULAR INSERTS COMPRISING A HYDROGEL AND CYCLOSPORINE | SUCLG1, FKBP8, FKBP1A | LMNA 3464/4885TSHR 4096/4885NFKB1 2192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.